Kamada vs Sinovac Biotech
KMDA and SVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KMDA and SVA compare
Kamada grew revenue faster over the last twelve months (13.2% versus 6.8% for Sinovac Biotech).
Sinovac Biotech scores higher on the StockData Score (6 against 5 for Kamada), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KMDA | SVA |
|---|---|---|
| Size and price | ||
| Share price | $8.09 | $6.47 |
| Change, 1 year | 11.1% | 0.00% |
| Change, 5 years | 44.5% | 0.00% |
| Beta (5Y) | 0.76 | 0.00 |
| Employees | 393 | 2,602 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 13.2% (better) | 6.8% |
| Revenue growth, 5Y average | 6.3% (better) | −5.4% |
| EPS growth (TTM) | – | −165% |
| EPS growth, 5Y average | −1.6% | – |
| Profitability | ||
| Gross margin | 40.8% | 67.9% (better) |
| Operating margin | 14.5% (better) | −127% |
| FCF margin | – | −145% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −0.54 | – |
| Interest coverage | 26.8× | – |
| Current ratio | 4.06 | 4.59 (better) |
| Dividends and buybacks | ||
| Years of dividend growth | – | 0 |
| Ownership | ||
| Held by institutions | 8.6% | 14.6% |
| Held by insiders | 45.3% | 65.7% |
| Insider net buying, 12 months | −$1.7M | – |
| Short interest, % of float | 0.53% | 0.33% |
Go deeper
- KMDA stock overview
- KMDA income statement
- KMDA valuation and score
- SVA stock overview
- SVA income statement
- SVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.